Table of Contents Author Guidelines Submit a Manuscript

Novel Cancer Immunotherapies and Antitumor Immunity

Call for Papers

Nowadays, antibody has been widely used in cancer treatment. However, due to the complexity and heterogeneity of cancer, the acquired resistance is one of the prime obstacles in the way of cancer treatment and development of novel cancer immunotherapies with potent antitumor activities and specificities are urgently needed. Recently, the success of PD-1/PD-L1 therapeutic antibodies in clinic has revealed that blockade of tumor-associated immunosuppression and initiation of tumor-specific immunity could be critical for the development of novel immunotherapies against cancer. How to efficiently induce tumor-specific immunity would be important for the development of novel cancer immunotherapies in the future.

The high-quality original research articles as well as review articles are invited to understand and clarify the related knowledge and mechanism of antitumor immune response and contribute to the development of novel cancer immunotherapies with high efficacy to induce antitumor immunity.

Potential topics include but are not limited to the following:

  • Tumor microenvironment and antitumor immunity
  • Restoration of immunoactive microenvironment for antitumor immunity
  • Alleviation of immunosuppressive microenvironment for antitumor immunity
  • Design of novel cancer immunotherapies, including strategies or agents to modulate antitumor immunity
  • Biomarkers for personalizing cancer immunotherapy, including immune-checkpoint blockade or immune cell therapy
  • New drug carriers, especially nanoparticles, for cancer target drug delivery

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 3 August 2018
Publication DateDecember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

  • Lei Zhao, PLA General Hospital, Beijing, China

Guest Editors

  • Jianjun Zhang, University of Texas MD Anderson Cancer Center, Houston, USA
  • Liang Xu, Beijing Institute of Pharmacology and Toxicology, Beijing, China